These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 30553470

  • 41. [Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].
    Zeng LP, Wen YL, Ma Y, Wang GQ, Li Y, Wang J, Xu LL, Zhang XM.
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):377-81. PubMed ID: 21914345
    [Abstract] [Full Text] [Related]

  • 42. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
    Pina-Oviedo S, Bellamy WT, Gokden M.
    Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
    [Abstract] [Full Text] [Related]

  • 43. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T, Jia Q, Wang Y, Liu Y, Han D, Li P, Ma J, Fan L, Yan Q, Guo S, Li M, Wang Z.
    Diagn Pathol; 2019 May 20; 14(1):45. PubMed ID: 31109360
    [Abstract] [Full Text] [Related]

  • 44. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.
    Caponetti GC, Dave BJ, Perry AM, Smith LM, Jain S, Meyer PN, Bast M, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Aoun P, Fu K, Greiner TC, Chan WC, Sanger WG, Weisenburger DD.
    Leuk Lymphoma; 2015 May 20; 56(11):3082-9. PubMed ID: 25827211
    [Abstract] [Full Text] [Related]

  • 45. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
    Pfreundschuh M.
    J Clin Oncol; 2012 Oct 01; 30(28):3433-5. PubMed ID: 22949148
    [No Abstract] [Full Text] [Related]

  • 46. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B, Salim O, Akkaya H, Ozcan M, Yucel OK, Erdem R, Iltar U, Undar L.
    Indian J Pathol Microbiol; 2016 Oct 01; 59(1):41-6. PubMed ID: 26960633
    [Abstract] [Full Text] [Related]

  • 47. Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.
    Clark Schneider KM, Banks PM, Collie AM, Lanigan CP, Manilich E, Durkin LM, Hill BT, Hsi ED.
    Leuk Lymphoma; 2016 Jul 01; 57(7):1640-8. PubMed ID: 26421520
    [Abstract] [Full Text] [Related]

  • 48. Double-Hit Large B Cell Lymphoma.
    Khelfa Y, Lebowicz Y, Jamil MO.
    Curr Oncol Rep; 2017 Sep 26; 19(11):74. PubMed ID: 28952038
    [Abstract] [Full Text] [Related]

  • 49. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
    Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJ, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH.
    Clin Cancer Res; 2014 Oct 01; 20(19):5113-23. PubMed ID: 25124685
    [Abstract] [Full Text] [Related]

  • 50. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A, Monabati A, Sadeghipour A, Radmanesh F, Safaei A, Movahedinia S.
    Ann Hematol; 2019 Jan 01; 98(1):169-173. PubMed ID: 30306208
    [Abstract] [Full Text] [Related]

  • 51. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N, Olson LC, Subramaniyam S, Hanson T, Magro CM.
    Am J Dermatopathol; 2016 Oct 01; 38(10):769-74. PubMed ID: 27391453
    [Abstract] [Full Text] [Related]

  • 52. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG, Martin V, Bernasconi B, Del Curto B, Pecciarini L, Uccella S, Pruneri G, Ponzoni M, Mazzucchelli L, Martinelli G, Ferreri AJ, Pinotti G, Assanelli A, Scandurra M, Doglioni C, Zucca E, Capella C, Bertoni F.
    Hum Pathol; 2009 May 01; 40(5):645-52. PubMed ID: 19144384
    [Abstract] [Full Text] [Related]

  • 53. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
    Batlle-López A, González de Villambrosía S, Francisco M, Malatxeberria S, Sáez A, Montalban C, Sánchez L, Garcia J, González-Barca E, López-Hernández A, Ruiz-Marcellan MC, Mollejo M, Grande C, Richards KL, Hsi ED, Tzankov A, Visco C, Xu-Monette ZY, Cao X, Young KH, Piris MÁ, Conde E, Montes-Moreno S.
    Oncotarget; 2016 Apr 05; 7(14):18036-49. PubMed ID: 26910115
    [Abstract] [Full Text] [Related]

  • 54. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
    Davies A.
    Hematology Am Soc Hematol Educ Program; 2017 Dec 08; 2017(1):284-294. PubMed ID: 29222268
    [Abstract] [Full Text] [Related]

  • 55. p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.
    Richardson AI, Zhang D, Woodroof J, Cui W.
    Hum Pathol; 2019 Apr 08; 86():21-31. PubMed ID: 30496802
    [Abstract] [Full Text] [Related]

  • 56. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS, Xue YQ, Yang HY, Zhang J, Pan JL.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr 08; 30(2):143-7. PubMed ID: 23568722
    [Abstract] [Full Text] [Related]

  • 57. Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy.
    Oh S, Koo DH, Suh C, Kim S, Park BH, Kang J, Huh J.
    J Korean Med Sci; 2011 Dec 08; 26(12):1556-62. PubMed ID: 22147991
    [Abstract] [Full Text] [Related]

  • 58. Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.
    Bashash M, Connors JM, Gascoyne RD, Meissner B, Schuetz JM, Leach S, Slack GW, Berry BR, Hu H, Sehn LH, Brooks-Wilson AR, Spinelli JJ.
    Haematologica; 2017 May 08; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract] [Full Text] [Related]

  • 59. [MYC-associated B-cell lymphomas: pathophysiology and treatment].
    Nitta H.
    Rinsho Ketsueki; 2019 May 08; 60(3):155-164. PubMed ID: 31068510
    [Abstract] [Full Text] [Related]

  • 60. [Clinical features in DLBCL and translocation BCL2/c-MYC "double hit" lymphoma].
    Škunca Ž, Domimis M, Plninc-Peraica A, Jakšić B.
    Acta Med Croatica; 2014 Jun 08; 68(3):299-305. PubMed ID: 26016222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.